sum of parts probably best way to value, you can also break it down further by regional license deal potential per asset.
VP-001 pre-clinical IP value box = US$100m license deal for a region
ignoring whether they get this upfront or per milestone, assume:
US $150k treatment price = 667 treatments to recover license costs
Depending on the geographic catchment, someone like Roche has the potential to cost recover in the first launch year, and derives profits annually thereafter
the more milestones to de-risk, the dearer the license cost will be per region. Bring on HREC/first dose!
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)